Introduction
============

The worldwide prevalence of AD is estimated at 35 million, a number expected to quadruple by 2050, due to the increasing lifespan of the world population ([@B46]). With an unfavorable prognosis and a life expectancy of approximately 8--10 years, AD is becoming one of the most costly diseases for society ([@B368]). In spite of increasing knowledge about the genetics, epidemiology, and histopathological features of AD there is, at this moment, only symptomatic treatment available. However, already at early clinical signs, intrinsic disease progression has developed for a long time; patients rapidly decline and develop irrevocable brain damage ([@B237]; [@B324]). Therefore, there is a great need for efficient treatment that should be initiated in a very early phase of the disease. Strict definite diagnosis can still only be made post-mortem, on the basis of two pathological hallmarks: SP and NFTs ([@B166]), although use of biomarkers is strongly advocated in research guidelines ([@B99]). More than 90% of clinical trials aiming to intervene at the causative pathological elements have failed to produce disease altering effects. A major concern hereby is the lack of objective biomarkers assisting in the evaluation of inclusion- and outcome criteria of participating patients, as many participants turned out to be misdiagnosed, particularly in the early AD disease stages ([@B174]; [@B22]; [@B177]). Currently five biomarkers for AD have been used for evaluation of disease and monitoring of disease progression ([@B174]): CSF levels of Aβ~42~, CSF levels of total tau and p-tau~181~ and p-tau~231~, structural imaging (CT and MRI) and functional imaging (PET with \[^18^F\]FDG). Elevated levels of CSF tau and reduced levels of CSF Aβ allow the prediction of, respectively, the NFT load and the SP deposits ([@B2]; [@B91]; [@B409]). Therefore, these CSF levels appear to be useful biomarkers in the diagnosis of AD ([@B393]; [@B396]). Nonetheless, CSF sampling requires an invasive lumbar puncture, quantification of CSF levels is hampered by interlaboratory variability and CSF values do not provide regional information on tau- and Aβ deposits. The regional concentration of tau- and Aβ deposits is however essential for a differential diagnosis of AD, especially among the different tauopathies ([@B142]; [@B131]; [@B140]). Structural volume measurement can be used to measure regional cerebral atrophy. Although not highly specific for AD due to overlap with 'normal' aging, the degree of atrophy follows neuropathological progression in AD and severity of volume loss correlates well with disease progression ([@B237]; [@B174]). Regarding the biomarkers that can be visualized and quantified by the molecular imaging techniques PET and SPECT, there are three important applications to be considered, that could contribute to successful drug development in clinical trials. The first one is the ability of PET and SPECT to provide quantitative and spatial *in vivo* assessment of, for example, the amyloid- and tau burden in AD patients. By doing so, inclusion and exclusion criteria in clinical trials can be verified more objectively than what was possible now with the previous biomarkers. Indeed, the use of specific radiotracers, for various targets, may provide accurate differential diagnosis (even at early AD stages) and true confirmation of the availability of the drug target, which allows physicians to reliably select patients for clinical trials to evaluate novel AD therapeutics ([@B22]). Another important role for these molecular imaging techniques is the assessment and quantitative follow-up of drugs aiming to intervene at the specific molecular pathophysiological processes. Using highly selective PET- or SPECT radioligands, the true biological effect of novel clinical candidates can be established and true quantitative assessment is possible ([@B22]). Thirdly, molecular imaging can be applied to measure the dose-related occupancy of specific targets caused by drugs under test, which allows the characterization of the optimal therapeutic window and thus a more effective design of subsequent clinical drug trials ([@B45]; [@B289]). Although PET is able to provide a much higher spatial resolution and dynamic scanning with higher temporal resolution and better quantification than SPECT, SPECT cameras are more widely available and cheaper than PET cameras. Both the availability and the economical aspect are important to consider when performing large multi-center clinical trials ([@B308]).

The most frequently used PET radiopharmaceutical is 2-\[^18^F\]fluoro-2-deoxy-[D]{.smallcaps}-glucose (\[^18^F\]FDG, **Figure [1](#F1){ref-type="fig"}**), a glucose derivative which allows measurement of brain glucose metabolism directly related with viability of brain tissue in AD ([@B22]). This commercially available compound, with various clinical applications, has been well established in routine clinical practice, but also in the recruitment and follow-up of the majority of AD clinical trials which use PET as biomarker technique ([@B22]). Indeed, several AD clinical trials are currently recruiting and following up patients with \[^18^F\]FDG (CTI: NCT02593318, NCT01561053, and NCT02560753). Although FDG-PET is able to provide information about regional glucose metabolism, which can aid in the detection and prognosis of MCI for further progression to AD, there is a great need for PET- and SPECT radiopharmaceuticals which deliver more target-specific information of a variety of (patho)physiological processes that are happening in AD. In this review we will therefore focus on some of the major molecular pathophysiological changes known to occur in AD, along with emerging pharmacological treatment approaches. Furthermore, specific attention will be attributed to the role that PET- and SPECT biomarkers (can) play during these clinical trials.
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Cholinergic Hypothesis
======================

Acetylcholinesterase
--------------------

The cholinergic hypothesis states that a decreased cholinergic neurotransmission, caused by a degeneration of cholinergic neurons in the basal forebrain, leads to several cognitive and functional conditions, associated with the symptoms of AD ([@B88]; [@B24]). Furthermore, the disruption of AChE seems to be associated with NFT- and Aβ deposits ([@B366]).

Acetylcholine, a neurotransmitter synthesized presynaptically by ChAT, is released in the synaptic cavity, where it is able to interact with nicotinic and muscarinic cholinergic receptors on pre- and postsynaptic membranes. Synaptic transmission is eventually stopped by the hydrolysis of ACh by AChE ([@B220]). Both ChAT and AChE expression is reduced in cortical regions of AD patients ([@B88]; [@B80]; [@B392]).

Inhibition of AChE was the first approach to treat AD, and this led to the FDA approval of eventually four AChE inhibitors: galantamine, rivastigmine, donepezil, and tacrine, though the latter one was largely discontinued due to hepatotoxicity issues ([@B408]). All inhibitors showed however only mild symptomatic improvement in patients with mild to moderate AD ([@B54]; [@B325]; [@B112]; [@B134]; [@B310]; [@B365]; [@B401]; [@B403]). Several new agents are currently under development ([@B7]), two of which have been evaluated in clinical trials: phenserine ([@B404]; [@B87]) and huperzine A ([@B307]). Phenserine, structurally related to rivastigmine, showed a prolonged, but mild inhibition of AChE in AD patients. Researchers suggested an add-on therapy with donepezil to improve the clinical efficacy of this class of agents. Low dosage of huperzine A, a reversible AChE inhibitor, showed no significant improvement on the ADAS-cog \[the primary cognitive outcome measure in mild to moderate AD patients (259)\], in a phase II trial in mild to moderate AD patients. Higher dosage and a long term evaluation were suggested by the authors. A phase III trial (CTI:NCT01282619) using sustained-release huperzine A is currently ongoing ([@B126]).

Visualization of the cholinergic system could be done by using radiolabeled ACh analogs or inhibitors of AChE ([@B366]; [@B169]; [@B172]; [@B199]). Both pathways have been pursued by researchers, but at present only two carbon-11 labeled compounds have been clinically evaluated on AD patients: \[^11^C\]MP4A and \[^11^C\]MP4P, two N-\[^11^C\]methylpiperidine esters (acetate and propionate, **Figure [2](#F2){ref-type="fig"}**). Moreover, both compounds were used to evaluate the effect of donepezil or rivastigmine in AD patients. Scans with \[^11^C\]MP4A or \[^11^C\]MP4P, taken before and after treatment with donepezil or rivastigmine, showed significant (up to 40%) cerebral cortical or frontal cortical inhibition of the AChE activity. Modest symptomatic improvement was recorded for all AD patients during these trials ([@B207]; [@B344]; [@B183]). These studies show the usefulness of both tracers for therapeutic monitoring of AChE inhibitors, as well as the possibility to evaluate newly developed drugs that target AChE ([@B345]). Nonetheless, carbon-11 labeled compounds have the limitation that an on-site cyclotron is needed, which limits their widespread use. The lack of significant cognitive improvement and the fact that the cholinergic deficit is not an early event in the development of AD ([@B127]), has challenged the cholinergic hypothesis ([@B117]; [@B23]; [@B367]; [@B76]). Nevertheless, two decades after FDA approval of tacrine, AChE inhibitors remain (out of necessity) the mainstay for the current symptomatic treatment of AD.
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Muscarinic ACh Receptor
-----------------------

The presynaptic cholinergic signal is transmitted through the release of the neurotransmitter ACh, which can interact with both muscarinic and nicotinic ACh receptors (the latter one discussed in the next section). The pre-and postsynaptic muscarinic ACh receptor (mAChR) is a plasmamembrane, GTP binding protein coupled receptor, of which five subtypes exist (M~1-~M~5~) ([@B38]; [@B292]; [@B37]). Due to the involvement in several neurological and psychiatric disorders, this target has been the topic of many research papers during the past few decades ([@B284]; [@B362]; [@B238]). A comprehensive autoradiography study using tritium labeled compounds on the distribution of M~1~--M~4~ muscarinic receptors of histopathological diagnosed AD patients by [@B323] showed that the decrease of M~1~ muscarinic receptors followed the general pattern of neurodegeneration as recorded in the Braak stages ([@B42]), while the M~2~ muscarinic receptor displayed significant reduction in the hippocampal area (up to 64%) and a significant increase in the striatum (up to 468% in the putamen), although this increase was not confirmed by other research groups ([@B106]). The density of M~3-4~ receptors on the other hand, was not altered compared to their density in brains of HCs. Interestingly, several research groups demonstrated that the stimulation of the M~1~- and M~3~ muscarinic receptors lead to an increase of the neuroprotective non-amyloidogenic pathway (formation of α-APP) ([@B56]; [@B258]). Stimulation of these receptors could thus provide means for a decrease in Aβ production, a hypothesis which was confirmed in several studies ([@B407]; [@B340]; [@B377]). Little is known about the M~5~ muscarinic receptor, the latest receptor to be cloned ([@B39]; [@B218]), although some research groups have demonstrated possible involvement in regulation of the cerebral blood flow and DA release ([@B414]).

A number of clinical trials have been carried out to examine the potential role of mAChR agonists/antagonists on the clinical symptoms of AD patients. In the group of the selective M~1~ agonists, talsaclidine showed a significant decrease (up to 27% compared to placebo) in the Aβ-CSF levels in a randomized, double-blind, placebo controlled trial on AD patients with a MMSE score between 12 and 26. Results should, however, be interpreted with some caution, as suggested by the researchers, since assessment of the amyloid burden in AD patients by CSF has some flaws as biomarker, furthermore there was no mention on any cognitive improvement alongside the drop in Aβ CSF levels ([@B157]). Yet, another M~1~selective agonist, cevimeline (AF102B), an FDA approved drug for the treatment of dry mouth in Sjögren's syndrome, did show cognitive improvement in the ADAS-cog and word recognition scales in a single-blind-placebo-controlled parallel group study with patients with probable AD ([@B114]). Dual selectivity for both the M~1~- and M~2~-receptor on the other hand, as it is the case for RS-86, showed no consistent cognitive improvement in a double-blind, placebo-controlled trial on mild to moderate AD patients ([@B50]). [@B283] hypothesized that RS-86' failure could be due to the concomitant stimulation of the M~1~- and M~2~ receptor, where stimulation of M~2~ might inhibit the effects of the M~1~ receptor. On the other hand, milameline, a partial agonist for all five muscarinic receptor subtypes, demonstrated an effect on the rCBF in the frontal and subcortical regions of AD patients as part of an 'add-on study' during a Phase III clinical trial of this drug. AD participants were evaluated with SPECT, using the cerebral blood flow tracer ^99m^Tc-exametazime (^99m^Tc-HMPAO), during the performance of two cognitive tasks. Although a modest increase (of 26%) of rCBF was demonstrated, the authors suggested that there maybe neuropsychopharmacological effects associated with the intake of milameline during the performance of cognitive demanding tasks ([@B374]). And finally, in a large-scale clinical trial, xanomeline, a M~1~- and M~4~-receptor agonist and M~5~ receptor antagonist ([@B133]), was evaluated in a randomized, double-blind, placebo-controlled trial on mild to moderate AD patients. Significant cognitive improvement was hereby shown in the ADAS-cog (drug vs. placebo; *p* ≤ 0.05), and the CIBIC+ scale (drug vs. placebo; *p* ≤ 0.02), demonstrating that a muscarinic receptor agonist can ameliorate cognitive symptoms in AD patients ([@B35]).

Only one imaging agent, with affinity for the M~1~- and M~4~ muscarinic receptor ([@B293]), has been clinically evaluated on AD patients thus far, namely \[^123^I\]I-quinuclidinyl benzilate ((R,R) \[^123^I\]I-QNB) (**Figure [3](#F3){ref-type="fig"}**). Eighteen mild to moderate AD patients and their age-matched HCs were evaluated with \[^123^I\]I-QNB. Significantly reduced uptake (*p* ≤ 0.001) was noted in the frontal rectal gyrus, right parahippocampal gyrus, left hippocampus, and regions of the left temporal lobe, compared to the HCs ([@B282]). Nevertheless, conflicting results have been reported by other research groups with this tracer ([@B159]; [@B395]; [@B410]; [@B190]), although the sample sizes in these other studies were smaller. In another study, \[^123^I\]I-QNB was used as a biomarker to evaluate the density of the mAChR on 20 patients receiving the AChE inhibitor donepezil ([@B48]). No distinction could be made between donepezil responders and non-responders, furthermore no positive correlation was found between \[^123^I\]I-QNB scans and the extent of cognitive improvement on the ADAS-cog scale, apart from the insular cortex, were an inverse correlation was found. Researchers suggest that response to donepezil may thus be greater in patients with clear cholinergic deficits. Several efforts have been made to develop carbon-11 and fluorine-18 labeled tracers for muscarinergic receptors ([@B111]; [@B105]; [@B412]). A clinical trial in the US with3-(3-(3-(\[^18^F\]fluoropropyl)thio)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine (\[^18^F\]FP-TZTP) ([@B311]; **Figure [3](#F3){ref-type="fig"}**), which binds to the M~2~ receptor, on AD patients has been completed (CTI: NCT00001917), but results are yet to be published. Lastly, recruitment for a study with HCs and AD patients using an M~4~ positive allosteric modulator \[^11^C\]MK-6884 (structure not yet available), will soon start (CTI: NCT02621606). Future PET- and SPECT compounds hold promise to evaluate inclusion- and outcome criteria with novel drugs targeting the muscarinic receptor, as well as to establish therapeutic windows via dose-occupancy studies.
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Nicotinic ACh Receptor
----------------------

nAChRs are ionotropic receptors, part of the ligand-gated ion channel superfamily ([@B77]; [@B61]; [@B81]; [@B379]). They consist of a hetero-or homopentameric structure, assembled from 17 possible subunits: α~1-10~, β~1-4~, γ, δ, and ε ([@B186]; [@B130]). The main subtypes of the nAChRs in the human CNS are, however, α~7~, α~4~β~2~, and α~3~β~2~, although the latter one is not involved in the pathophysiology of AD ([@B399]; [@B303]). Reduction in nAChRs expression levels of several subtypes has indeed been revealed in regions with dense deposits of Aβ and NFTs ([@B296]; [@B270]; [@B51]). The α~7~ nAChR is mainly expressed in the hippocampus, whereas the α~4~β~2~ nAChR is homogenously expressed throughout brain ([@B268]; [@B379]). While loss of α~4~β~2~ nAChR can cause memory deficits in AD patients ([@B290]; [@B268]; [@B194]), a more complex relationship has been noted when evaluating the interaction between α~7~ nAChR and Aβ in AD ([@B270]). Aβ can either interact as agonist or as antagonist of α~7~ nAChR, depending on its concentration, where low concentrations may activate and high concentrations may inactivate α~7~ nAChR ([@B98]; [@B302]; [@B334]). Observations in an AD transgenic mouse model overexpressing APP, presenilin-1, and tau (3xTg-ADmice) ([@B269]; [@B30]; [@B203]) were consistent with the aforementioned *in vitro* conclusions for human AD, demonstrating an age dependent reduction of α~7~ nAChR, as higher Aβ may eventually block remaining α~7~ nAChRs ([@B151]). For a more detailed discussion about the many different roles of nAChRs in AD, readers are referred to several reviews on the subject ([@B270]; [@B182]; [@B381]).

Since nicotine can induce the release of presynaptic ACh and is involved in the modulation of many other neurotransmitters, such as GABA, DA, norepinephrine, and serotonin ([@B217]), several clinical studies have investigated the effect of nicotine on AD patients ([@B180]; [@B402]; [@B349]; [@B400]). However, as mentioned in a review by [@B270], these trails failed to demonstrate any cognitive improvement in AD patients; only an increase in attention could be determined. Yet, clinical trials with two nAChR agonists did show cognitive improvement in mild to moderate AD patients ([@B300]; [@B92]). The first of them was encenicline (EVP-6124), a partial agonist of α~7~ nAChR. This drug was well tolerated in Phase I and II trials, showing significant improvement in cognitive and functional domains ([@B92]). A currently ongoing Phase III trial involving mild to moderate AD patients, receiving or having already received AChE inhibitors, to assess the efficacy and tolerability of EVP-6124 (ECT: 2012-003209-92) in a large group of patients was halted due to severe gastrointestinal side-effects ([@B346]). Another nAChR agonist, ABT-418, which has binding affinity for α~4~β~2~, α~2~β~2~, and α~3~β~4~ ([@B300]), showed some cognitive improvement in the acquisition and retention of verbal information of patients with early AD (Mean MMSE score of 21.4). It is, however, unclear whether this compound will be further pursued in large clinical trials. Two other trials with nAChR agonists were less convincing; efficacy of ispronicline (TC-1734 or AZD-3480) a selective agonist of α~4~β~2~ nAChR and α~2~β~2~ nAChR ([@B124]) was investigated in a large Phase IIb dose-finding study on mild to moderate AD patients (MMSE score: 12--26). Despite the fact that ispronicline caused significant improvement on patients with age-associated memory impairment ([@B100], [@B101]), no significant improvement could be shown on the ADAS-cog scale in the latest Phase IIb study, although secondary outcome measurements did show some improvement ([@B120]). Additional Phase II trials on mild to moderate AD patients were halted, since no superiority over donepezil could be demonstrated. Finally, in a Phase II trial on mild to moderate AD patients (MMSE score of 26--26 and 14--20, respectively), no cognitive improvement could be observed with the α~4~β~2~ nAChR selective agonist varenicline ([@B200]). Researchers concluded that the dosing regimen was not optimal and overall longer (than 6 weeks) trials may be needed to show cognitive improvement. In the light of these two failed clinical trials with α~4~β~2~ nAChR agonists, another clarification could, however, be that the α~4~β~2~ nAChR subtype may only play a minor role on cognitive processes in AD, and α~7~ nAChR is therefore a more suitable target ([@B200]).

While nicotine was not really used as a therapeutic drug, as a carbon-11 labeled PET tracer it successfully showed reduction of nAChR in AD patients reflecting the loss of the nicotinic receptors during disease progression, in comparison with control subjects ([@B262]; [@B265]; [@B184]). Additionally, a number of other clinical studies used \[^11^C\]nicotine PET imaging (**Figure [4](#F4){ref-type="fig"}**), to assess the efficacy of the AChEIs tacrine and rivastigmine ([@B263]; [@B264]; [@B261]; [@B185]). Significant increase in nAChR expression compared to baseline in several cortical areas could be demonstrated, after treatment with both tacrine and rivastigmine. \[^11^C\]nicotine does, however, show high non-specific binding and rapid brain wash-out, making quantitative PET assessments of nAChR difficult. A few other PET radiotracers are currently under development for imaging of α~7~ and α~4~β~2~ nicotinic receptors ([@B372]; [@B243]; [@B63]); two structurally related compounds, one SPECT and one PET tracer, with affinity for the α~4~β~2~ nicotinic receptor have already been evaluated on AD patients ([@B268]; [@B109]; [@B333]). Reduced tracer uptake was noted in AD patients in the frontal lobe, striatum, right medial temporal lobe and the pons after scans with-5-\[^123^I\] iodo-3-\[2(S)-2-azetidinylmethoxy\]pyridine (\[^123^I\]5IA-85350) (**Figure [4](#F4){ref-type="fig"}**), consistent with known reductions of the α~4~β~2~ nicotinic receptor in AD ([@B268]). Its PET counterpart, 2-\[^18^F\]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-\[^18^F\]FA-85380) (**Figure [4](#F4){ref-type="fig"}**), was able to demonstrate significant reduction (up to 75%) of the α~4~β~2~ nicotinic receptor in MCI patients, which later on converted to AD ([@B333]). In another study with 2-\[^18^F\]FA-85380, the possible relationship between Aβ depositions and the reduction of the α~4~β~2~ nicotinic receptor was studied by evaluating early to moderate AD patients ([@B271]). A negative correlation between the presence of Aβ in the medial frontal cortex and the nucleus basalis magnocellularis, as assessed by \[^11^C\]Pittsburgh Compound B (\[^11^C\]PiB, an Aβ tracer), and the binding of 2-\[^18^F\]FA-85380 to the α~4~β~2~ nicotinic receptor could be established. Both α~4~β~2~ nicotinic receptor tracers suffer, however, from slow kinetics, leading to long scanning times, making routine application difficult ([@B243]). Conversely, a novel α~4~β~2~ nAChR tracer, 2-{5-\[2-\[^18^F\]fluoropyridin-4-yl\]pyridin-3-yl}-7-methyl-7-azabicyclo\[2.2.1\]heptane (\[^18^F\]XTRA) ([@B243]) (**Figure [4](#F4){ref-type="fig"}**), showed much faster pharmacokinetics, which allow scanning within a reasonable time frame. Recruitment for a clinical trial with \[^18^F\]XTRA on HCs, an AD or a MCI patient is currently ongoing (CTI:NCT01894646).
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Tau Hypothesis
==============

As one of the pathological hallmarks in well over 20 neurodegenerative diseases ([@B214]), tau (*tubulin associated unit*), gained an increasing interest in the past few years, partly as a result of the large failure rate of clinical trials targeted toward the amyloid hypothesis ([@B22]), but also due to recent availability of several tau specific PET ligands ([@B388]). As a member of the microtubule-associated protein (MAP) family, tau is mainly localized in the distal part of the neuronal axons ([@B31]). Consequently, the primary function of tau is stabilization and support of the microtubules ([@B397]). There are six different isoforms of tau, depending on alternative splicing of exon two, three, and ten of the MAPT. Localized on chromosome 17q32, this gene contains 16 exons ([@B256]). Exon two and three both encode a 29-aminoacid fragment at the N-terminal part of tau, yielding isoforms with none (0N), one (1N), or two inserts (2N). Exon ten on the other hand, encodes a 31-aminoacid fragment, which results in either three (3R) or four (4R) repeated binding domains at the C-terminus of the protein. The mature human brain contains thus six isoforms of tau: 0N3R, 1N3R, 2N3R, 0N4R, 1N4R, and 2N4R. Under normal conditions (and in AD) there is a 1:1 ratio of the 3R- and 4R isoforms, but this ratio somehow shifts in certain pathological conditions ([@B160]). The exact physiological role of these various isoforms remains to be elucidated, although 4R isoforms are better at promoting microtubuli assembly, and have greater binding affinity for microtubuli than the 3R isoforms ([@B128]; [@B55]). Under non-pathologic conditions, tau is a highly soluble protein with a limited secondary structure ([@B102]), prone to several post-translational modifications. The most important one is phosphorylation on its serine and threonine residues, which modulates microtubule binding ([@B233]). Then again, in pathological conditions, such as AD, tau will become hyperphosphorylated, detaches from the microtubules and will self-aggregate into insoluble PHFs and NFTs, compromising neuronal cell function ([@B168]). Different shapes and sizes of the aggregates can be found under diverse cognitive conditions, related to the presence of various isoforms, and post-translational modifications ([@B14]). In AD, the spreading of the tau pathology, which is thought to proceed in a prion-like manner ([@B89]), has been well-documented in the different Braak stages ([@B42]). Furthermore, several studies confirmed that this characteristic pattern of aggregated tau spread closely correlates to the clinical symptoms of AD, as measured by the MMSE ([@B15], [@B16]; [@B103]; [@B135]). This makes tau an interesting target for drug development. Due to the complexity of aggregated tau as a drug target, several tau-associated approaches have been investigated.

Glycogen synthase kinase 3β, being the dominant isoform of three GSK-3 variants ([@B179]), is the main kinase responsible for the hyperphosphorylation of tau, and hence an important potential target for disease-modification ([@B230]). Diverse GSK-3 inhibitors were reported the last few years by many research groups ([@B260]; [@B27]; [@B230]). Lithium and valproate were the first compounds to be clinically evaluated, but due to inconsistent and overall disappointing results, they were largely discontinued ([@B259]; [@B141]; [@B363]; [@B364]). Several other GSK-3 inhibitors have, however, been pursued ([@B230]), two of which, tideglusib (NP0311212) and AZD1080, entered clinical trials ([@B201]; [@B223]). Development of AZD1080 was, however, halted in Phase I due to nephrotoxicity problems ([@B108]) and no clinical benefit was seen with tidelusib on patients with mild to moderate AD in Phase II clinical trials. Dose finding studies and longer trials are now required with the latter drug to examine its possible long term benefit ([@B223]). Another tau-associated approach is the inhibition of tau-aggregation ([@B53], [@B52]). The first of this class to be pushed in Phase II clinical trials, methylthioninium chloride (methylene blue, MTC), a phenothiazine derivative, was able to stabilize disease progression over a period of 50 weeks in mild and moderate AD patients ([@B406]). The brain bioavailability of this charged drug remains, however, to be elucidated. The pro-drug of MTC, leuco-methylthioninium (TRx0237 or LMTX), with a superior pharmacological profile ([@B405]) will now be evaluated in three parallel Phase III trials on mild to moderate AD patients and patients with FTD (CTI: NCT01689246, NCT01689233, and NCT01626378). And finally, an increasing interest toward tau immunotherapy has been noted, as means of removing tau aggregation by the patients' own immune system ([@B10]). Two drugs of this kind, ACI-35 (ECT: 2015-000630-30) and AADvac1 (CTI: NCT02031198) are currently being evaluated in Phase I and II trials.

Despite the historical importance of tau as a pathological hallmark in AD ([@B132]), only recently tau specific PET ligands have been developed. One of major issues during tau PET development is the lack of a representative tau-animal model, which may be explained by (ultra)structural differences between murine and humane tau ([@B104]). More than a few tracers are, however, currently being clinically evaluated. The first tau PET ligand to be reported was 2-(1-{6-\[(2-\[^18^F\]fluoroethyl)(methyl)amino\]-2-naphthyl}ethylidene)malononitrile (\[^18^F\]FDDNP) (**Figure [5](#F5){ref-type="fig"}**), although not specific for tau as such, high binding affinity was reported in several neurodegenerative diseases ([@B44]; [@B347]; [@B197]; [@B254]; [@B196]; [@B348]). Limited dynamic range of signal and relatively low affinity for tau, led to the development of novel tau directed ligands with similar structural moieties. Yet, the first real approach toward tau specific ligands was achieved by researchers of the Tohoku University in Japan with the development of 4-{6-\[2-\[^18^F\]fluoroethoxy\]quinolin-2-yl}aniline (\[^18^F\]THK523) ([@B115]) (**Figure [5](#F5){ref-type="fig"}**). While \[^18^F\]THK523 was able to visualize the known pattern of tau distribution in AD patients, high white matter binding and unfavorable pharmacokinetics ([@B389]) led to the development of three novel 2-arylquinoline derivatives: 1-({2-\[4-(dimethylamino)phenyl\]quinolin-6-yl}oxy)-3-\[^18^F\]fluoropropan-2-ol (\[^18^F\]THK5105) ([@B272]), 1-\[^18^F\]fluoro-3-({2-\[4-(methylamino)phenyl\]quinolin-6-yl}oxy)propan-2-ol (\[^18^F\]THK5117) ([@B170]) and the optically pure (2S)-1-\[^18^F\]fluoro-3-({2-\[4-(methylamino)phenyl\]quinolin-6-yl}oxy)propan-2-ol (\[^18^F\]THK5351) ([@B144]) (**Figure [5](#F5){ref-type="fig"}**). All three compounds showed high binding in AD patients, with radiotracer retention in sites known for their tau deposition. Of these three compounds, \[^18^F\]THK5351 showed superior pharmacokinetics, highest signal-to-noise ratio and the lowest white matter binding ([@B273]; [@B144]). Further clinical trials in Japan with \[^18^F\]THK5351 are underway (UMIN-CTR: UMIN000013929 and UMIN000018496). Often considered by many research groups as the current benchmark in tau PET development, 11-{4-\[2-\[^18^F\]fluoroethyl\]piperidin-1-yl}-1,8,10-triazatricyclo\[7.4.0.0^2,7^\]trideca-2(7),3,5,8,10,12-hexaene (\[^18^F\]T808 or \[^18^F\]AV680), and 2-\[^18^F\]fluoro-5-{5H-pyrido\[4,3-b\]indol-7-yl}pyridine (\[^18^F\]T807 or \[^18^F\]AV1451) (**Figure [5](#F5){ref-type="fig"}**) have high affinity and selectivity for tau over Aβ ([@B419]; [@B411]; [@B343]). A small first-in-man study with \[^18^F\]T808 in eight AD patients (mean MMSE of 18) and their three age matched HCs, showed a rapid brain uptake and washout in HCs, and a tau pattern consistent with the Braak stages in the AD group ([@B68]). Interestingly, one of the AD patients who died a few weeks after his PET scan with \[^18^F\]T808, showed close correlation with his histopathological staining ([@B86]). Nonetheless, substantial bone uptake was observed with this compound ([@B388]), which led to the development of \[^18^F\]T807. In comparison to \[^18^F\]T808, \[^18^F\]T807 has slower kinetics and a relatively lower affinity for tau, but \[^18^F\]T807 does not show defluorination ([@B411]). Similar clinical findings as with \[^18^F\]T808 were demonstrated with \[^18^F\]T807 in a small first-in-man study on three HCs, in one patient with MCI (MMSE score of 26) and one severe AD patient (MMSE score of 7) in comparison with three HCs. Remarkably, the tracer retention was significantly lower in the patient with MCI, as compared to the patient with severe AD ([@B67]). A series of large clinical trials (ClinicalTrial.gov and EU Clinical Trials Register: search term: 'T807' OR 'AV1451' AND 'PET') is underway with \[^18^F\]T807 to evaluate its applicability not only in AD, but also in several other tauopathies. Being thus far the only compound to be able to visualize tau (and possibly different isoforms) in AD, but also in PSP and CBD ([@B236]), 2-((1E, 3E)-4-(6-(\[^11^C\]methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo\[d\]thiazol-6-ol (\[^11^C\]PBB3) received a lot of interest (**Figure [5](#F5){ref-type="fig"}**). Clinical studies on AD patients and a CBD patient, as compared to HCs, showed increased tracer uptake, consistent with the Braak stages (for the AD case), and higher retention in the basal ganglia (for the CBD case). Stability issues and a challenging radiosynthesis might, however, limit its commercial use. Several other tau directed PET ligands from Roche, such as \[^11^C\]RO6931643, \[^11^C\]RO6924963, and \[^18^F\]RO6958948 (structures not available) have been evaluated in a Phase I clinical trial, but data are yet to be published (CTI: NCT02187627) ([@B86]). Other clinical studies with \[^18^F\]MK-6240, \[^18^F\]MNI-798, and \[^18^F\]MNI-815 (structures not available) on AD cases are currently recruiting patients (CTI: NCT02562989, NCT02640092, and NCT02531360). For a more detailed discussion about the current state of tau PET development, readers are referred to some excellent reviews on the subject ([@B273]; [@B421]; [@B86]). An important question that remains to be elucidated is for which isoforms these tau PET tracers have affinity; a question which may have major implications on the differential diagnosis of closely related neurodegenerative tauopathies. Nevertheless, the substantial progress that has been made in this field will make it possible to allow *in vivo* detection of tau in AD and thus the reassessment of inclusion- and outcome criteria of clinical trials aiming to intervene at tau-aggregates.

![**Structure of tau PET tracers**.](fphar-07-00088-g005){#F5}

Amyloid Hypothesis
==================

For many decades, the amyloid hypothesis has been the main pathological model of AD ([@B148]; [@B205]), accepted by most researchers, and only recently contested ([@B146]). It postulates that extensive deposits of amyloid in the human brain are the central lesions in the development of AD, responsible for a neurotoxic cascade of events, which ultimately leads to dementia ([@B18]). Aβ peptides, the main component of SP ([@B129]), are 39--43 amino acid residues, formed during the sequential cleavage of the transmembrane APP by β-secretase 1 (also called BACE1) ([@B137]), followed by the action of the γ-secretase ([@B342]). Under 'normal' conditions APP is cleaved in a non-amyloidogenic pathway by the action of initially α-secretase, forming α-sAPP, which may have a neuroprotective function ([@B281]). α-sAPP is then further cleaved by γ-secretase to eventually produce P3. The function of APP itself is unknown, although a possible role in the Cu-homeostasis has been proposed ([@B20]). There are two main isoforms of Aβ: Aβ~40~ and Aβ~42~, the latter one being more prone to aggregation and regarded as the main neurotoxic species ([@B12]). Once formed, Aβ species will undergo several characteristic changes, from small oligomers into larger fibrils, which eventually form diffuse and later neuritic plaques. These plaques frequently trigger astrocytosis, activation of microglial cells, cytokine release, and a multi-protein neuroinflammatory response ([@B18]). Just like the NFTs, amyloid depositions follow a specific pattern, as recorded by [@B42]. In contrast to the NFTs, however, there is a poor correlation between the extent of these plaques and the degree of cognitive impairment ([@B255]), furthermore non-demented individuals can heave substantial loads of Aβ deposition without revealing any clinical symptoms ([@B391]). Recently, several studies pointed toward Aβ oligomers, and not amyloid plaques, as the main toxic species in AD ([@B138]; [@B247]). For a more extensive discussion about the neuropathological role Aβ plays in AD, readers are referred to other reviews ([@B138]; [@B147]; [@B18]).

Huge efforts have been undertaken to develop disease altering drugs that target the amyloid deposition, but unfortunately many failed during clinical trials ([@B22]). Some of the most recent *ongoing* trials targeting the amyloid deposits are summarized in **Table [1](#T1){ref-type="table"}**. Various therapeutic approaches are to be considered when targeting Aβ ([@B18]). We will discuss here the most important tactics, together with some of their constraints, as it is imperative to know why so many trials fail in this area. One of many methods applied, is the reduction of Aβ production through inhibition of β-and/or γ-secretase or activation of α-secretase ([@B83]). Indeed, the therapeutic potential of BACE1 inhibitors has been demonstrated in BACE1 knockout mice, which produced significantly (15-fold) less Aβ ([@B225]; [@B320]). Nonetheless, inhibition of BACE1 causes several problems, since BACE1 has been shown to have many physiological roles, which might lead to toxicity problems when using BACE1 inhibitors. Furthermore, BACE1 inhibitors need to be quite bulky, due to the relatively large active site and this can cause BBB passage issues ([@B126]). Inhibition of the multimeric γ-secretase complex encounters similar problems as the use of BACE1 inhibitors, as γ-secretase has many other physiological roles as well, especially cleavage of the Notch receptor, necessary for growth and development ([@B416]). Brain penetration seems to be an issue as well in this area ([@B167]). Increasing the α-secretase activity, and thus promoting the non-amyloidogenic pathway, is another way to reduce the Aβ load. Less is however known about the possible physiological consequences of such an upregulation ([@B18]). Another way of interfering with the Aβ load is by modulation of Aβ aggregation, as increasing evidence suggests that soluble oligomers, which act as intermediates for the formation of aggregates, are the most toxic species in AD disease ([@B84]; [@B162]; [@B188]). Yet, the most promising small molecules ultimately failed due to their (toxic) pharmacological profile ([@B335]; [@B318]; [@B416]). Several studies also showed the relationship of APP and Aβ with mitochondrial dysfunction in AD ([@B5]; [@B226]; [@B60]); interaction of both proteins with mitochondrial matrix proteins, such as Aβ-binding alcohol dehydrogenase and adenosine triphosphate synthase subunit alpha, could directly lead to mitochondrial toxicity, and thus oxidative stress ([@B96]; [@B312]). Numerous antioxidant agents have been described and evaluated in clinical trials with MCI- and AD patients, and several studies are still ongoing ([@B241]; [@B298]). Conflicting results were, however, reported and overall small cognitive benefit was seen during these trials. Long-term trails are now warranted in order to establish clinical benefits in AD. Then again, several promising antioxidative compounds are currently being investigated ([@B304]; [@B316]). Still, the primary action in targeting amyloid came from monoclonal antibodies. First discovered by [@B341] to be very effective in reducing the Aβ load in mice, the mechanism of action of amyloid immunotherapy remains, however, to be fully elucidated ([@B416]). Nevertheless, only a small fraction (0.1% of the injected dose) of antibodies seems to be able to pass the BBB in humans ([@B17]). A higher fraction of antibodies in the brain may thus be needed to be therapeutically effective. This hurdle was the topic of two recently reported reviews ([@B216]; [@B354]). Despite the low BBB's passage, one of the major concerns with immunotherapy is the development of serious side effects, for instance encephalitis (active immunization), microhemorrhages, or vasogenic edemas (passive immunization) ([@B275]; [@B285]). Another important factor to consider is the time of intervention in the AD state; immunotherapy is probably most efficacious in early disease states, when there is more function to preserve ([@B22]). Efficient biomarkers, that can predict the conversion from MCI to AD, are therefore of utter importance. Using longitudinal PET biomarkers to assess and follow up the amyloid burden in clinical trials would indeed allow a more confident formulation of inclusion, but also outcome criteria ([@B22]). Several amyloid PET tracers are currently being used for these purposes (see **Table [1](#T1){ref-type="table"}**).

###### 

Ongoing clinical trials with drugs targeting the amyloid hypothesis ([@B143]; [@B405]; [@B8]).

  Drug           Approach                Trial phase   CTI              PET biomarker\*                 EudraCT number
  -------------- ----------------------- ------------- ---------------- ------------------------------- ----------------
  MK-8931        BACE1 inhibitor         3             NCT01953601      \[^18^F\]flutemetamol           2012-005542-38
                                         2/3           NCT01739348      \[^18^F\]flutemetamol           2011-003151-20
  AZD3293        BACE1 inhibitor         2/3           NCT02245737      \[^18^F\]AV-45 / \[^18^F\]FDG   2014-002601-38
  PF-03084014    γ-secretase inhibitor   2             NCT01981551      Not specified                   /
  NIC5-15        γ-secretase inhibitor   2             NCT01928420      Not specified                   /
  Bryostatin-1   α-secretase enhancer    2             NCT00606164      Not specified                   /
                                         2             NCT02431468      Not specified                   /
  Solanezumab    Passive immunization    2/3           NCT01760005      \[^11^C\]PiB / \[^18^F\]FDG     2013-000307-17
                                         3             NCT01900665      \[^18^F\]AV-45                  2013-001119-54
  Gantenerumab   Passive immunization    3             NCT02051608      \[^18^F\]AV-45                  2013-003390-95
                                         3             NCT01224106      Not specified                   2010-019895-66
                                         2/3           NCT01760005      \[^11^C\]PiB / \[^18^F\]FDG     2013-000307-17
  Crenezumab     Passive immunization    1             NCT02353598      \[^18^F\]AV-45                  /
                                         2             NCT01998841      Not specified                   /
                                         2             NCT01723826^C^   Not specified                   2012-003242-33
  BAN2401        Passive immunization    2             NCT01767311      Not specified                   2012-002843-11
  Gammagard      Passive immunization    2/3           NCT01561053      \[^18^F\]FDG                    /
  Aducanumab     Passive immunization    3             NCT02484547      Not specified                   2015-000967-15
                                         3             NCT02477800      Not specified                   2015-000966-72
                                         1             NCT02434718      Not specified                   /

\*C = Completed; PET biomarkers are either used as inclusion criteria and/or as outcome measure.

Although not FDA-approved, 2-{4-\[\[^11^C\]methylamino\]phenyl}-1,3-benzothiazol-6-ol (\[^11^C\]PiB) (**Figure [6](#F6){ref-type="fig"}**) has been used for many years as benchmark compound for *in vivo* imaging of the amyloid load in AD patients ([@B26]). Results of those trials have shown that clinically diagnosed AD cases have positive amyloid scans ([@B193]; [@B175], [@B176]; [@B224]), and the ones that did not have positive scans, were most likely to be misdiagnosed ([@B305]; [@B306]). Furthermore, increased \[^11^C\]PiB binding is able to predict the conversion of MCI to AD ([@B274]). \[^11^C\]PiB has also been proven useful in the differential diagnosis of FTD and AD, as FTD patients typically have a normal \[^11^C\]PiB uptake ([@B327]; [@B110]). Interestingly, a close correlation has been noted with CSF Aβ levels ([@B370]; [@B394]), firmly establishing \[^11^C\]PiB as an Aβ biomarker. There are, however, a few limitations with \[^11^C\]PiB as an amyloid biomarker; \[^11^C\]PiB presumably binds to diffuse plaques and not to the more cognitive correlated neuritic plaques ([@B173]). Moreover, commercial use is excluded, due to the short half-life of carbon-11. Several attempts were thus undertaken to develop ^18^F-labeled analogs ([@B204]). Three of them: 4-\[(E)-2-\[6-(2-{2-\[2-\[^18^F\]fluoroethoxy\]ethoxy}ethoxy)pyridin-3-yl\]ethenyl\]-*N*-methylaniline (\[^18^F\]florbetapir or \[^18^F\]AV-45), 2-\[3-\[^18^F\]fluoro-4-(methylamino)phenyl\]-1,3-benzothiazol-6-ol (\[^18^F\]flutemetamol, \[^18^F\]GE-067 or \[^18^F\]AV-1) and 4-\[(E)-2-\[4-(2-{2-\[2-\[^18^F\]fluoroethoxy\]ethoxy}ethoxy)phenyl\]ethenyl\]-*N*-methylaniline(\[^18^F\]florbetaben or \[^18^F\]BAY 97-9172) (**Figure [6](#F6){ref-type="fig"}**) have already been approved by the FDA and the EMA for their binding to neuritic plaques. Another one, 2-\[2-\[^18^F\]fluoro-6-(methylamino)pyridin-3-yl\]-1-benzofuran-6-ol (\[^18^F\]AZD-4694 or \[^18^F\]NAV4694) (**Figure [6](#F6){ref-type="fig"}**), is currently awaiting FDA-approval ([@B173]). Although all of the current ^18^F-labeled compounds show significant increased uptake in AD patients as compared to HCs in clinical trials ([@B326], [@B328]; [@B21]; [@B390]), they suffer from high non-specific white matter binding, as compared to \[^11^C\]PiB ([@B26]; [@B329]; [@B380]). Only \[^18^F\]AZD-4694 has a white matter uptake similar to \[^11^C\]PiB ([@B328]). While a negative amyloid PET scan will exclude AD, a positive scan, on its own, is insuffient for the diagnosis of AD, as has been shown with \[^18^F\]florbetapir in clinic ([@B415]). Furthermore, limited reimbursement of these recently approved compounds limits their use in clinical practice ([@B22]). The use of amyloid PET may, however, reveal true AD cases. Moreover, the amyloid tracers are able to predict the conversion from MCI to AD, and this can considerably influence decision making in AD related clinical trials ([@B329]).

![**Structure of Aβ PET tracers**.](fphar-07-00088-g006){#F6}

Gamma-Aminobutyric Acid Receptors
=================================

The inhibitory GABA system in the CNS consists of three GABA receptor systems: GABA~A~, GABA~B~ and GABA~C~ ([@B64]). Since GABA~B~- and GABA~C~ receptors have not been clinically evaluated in AD yet, focus will be toward the GABA~A~ receptor. The GABA~A~ receptor is a pentameric ligand gated ion channel, composed of a wide array of (possible) subunits: α~1-6~, β~1-3~, γ~1-3~, δ, ε, τ, π, and ρ~1-3~ ([@B242]). In order to be functional, the receptor seems to require the presence of at least one α- and one β-subunit. The most common composition is a pentamer composed of two α-, two β-, and one γ-subunit ([@B74]). The GABA system plays an important role in AD, as it is one of the main culprits for the BPSD. Contributing to these BPSD, the GABA system is also known to modulate other neurotransmitters, such as serotonin, DA and ACh ([@B93]; [@B422]; [@B198]). It has been a long standing, although contested ([@B213]), view that the GABA system undergoes little change during AD progression, due to dynamic plasticity of the system ([@B319]). Recent findings suggest, however, otherwise and point to a severely altered GABAergic signaling in AD, with possible modulation of tau hyperphosphorylation ([@B213]; [@B219]; [@B266]). A more detailed discussion of the GABAsystem and its putative role in AD can be found in some extensive reviews ([@B231]; [@B213]; [@B319]).

Benzodiazepines, which are allosteric modulators of the GABA~A~ receptor ([@B153]), have long been used for the symptomatic treatment of anxiety and agitation in AD ([@B202]; [@B79]; [@B359]; [@B418]), nevertheless there is a need for randomized controlled trials to evaluate the true efficacy of these drugs in AD ([@B94]). Caution is also to be advised with BZDs, as there are reports of rapid cognitive and functional decline in AD patients when taking these drugs for an extensive period of time ([@B418]).

There have been numerous endeavors to developed radiotracers for *in vivo* imaging of the GABA~A~ receptors ([@B187]; [@B6]). Ethyl 12-fluoro-8-\[^11^C\]methyl-9-oxo-2,4,8-triazatricyclo\[8.4.0.02^2,6^\]tetradeca-1,3,5,10,12-pentaene-5-carboxylate (\[^11^C\]flumazenil) (**Figure [7](#F7){ref-type="fig"}**), a GABA~A~antagonist with affinity for the α~1-3~ and α~5~-subunit, is the most promising tracer thus far. Several clinical studies have been performed with \[^11^C\]flumazenil ([@B339]; [@B149]; [@B119], [@B118]; [@B6]), one of which was carried out on early AD patients (Mean MMSE: 21.2) to evaluate the GABA~A~ receptor density. Researches demonstrated a marked decrease in \[^11^C\]flumazenil binding, which correlated well with neuronal loss as evaluated by histopathological findings ([@B49]; [@B6]). The SPECT analog ethyl 11-\[^123^I\]iodo-8-methyl-9-oxo-2,4,8-triazatricyclo\[8.4.0.0^2,6^\]tetradeca-1,3,5,10,12-pentaene-5-carboxylate (\[^123^I\]iomazenil) (**Figure [7](#F7){ref-type="fig"}**), showed significantly reduced uptake in the temporal, parietal end occipital cortex of moderate to severe AD patients ([@B351]; [@B121]). In contrast to \[^11^C\]flumazenil though, \[^123^I\]iomazenil was not able to show significant changes in early AD patients ([@B288]). Interestingly, in a direct PET-SPECT comparison study on healthy volunteers between \[^11^C\]flumazenil and \[^123^I\]iomazenil, the ^123^I-labeled variant came out as the better candidate, due to a better fit in compartmental modeling with SPECT ([@B43]). These radiopharmaceuticals not only hold promise to be used as inclusion- and outcome criteria for drugs combatting BPSD symptoms in AD, but they could also be used in dose-occupancy studies to assess the (sometimes small) therapeutic window of BZDs.

![**Structure of GABAergic PET/SPECT tracers**.](fphar-07-00088-g007){#F7}

Serotonergic System
===================

Serotonin (5-HT), is a neurotransmitter that plays a complex role in the modulation of several psychological, emotional, and cognitive processes. Moreover, 5-HT affects long-term and short-term memory and cognitive function through the regulating of many other neurotransmitters, such as ACh, DA, GABA, and glutamate ([@B322]). The principal 5-HT-source in the human brain comes from neurons in the raphe nuclei, with various projections throughout the CNS ([@B386]; [@B387]). There are seven main 5-HTRs, which can be divided into two major classes: the G-protein coupled receptors (5-HTR~1,2,4-7~) and the ligand-gated cation channels (5-HTR~3~), many of which have also several subcategories ([@B164]). For the 'normal' physiological and pharmacological role of these receptors, readers are referred to several reviews on the topic ([@B19]; [@B164]; [@B257]). An overall reduction of the serotonergic system in AD pathology, likely reflecting the loss of serotonergic projections from the raphe nuclei, has been demonstrated ([@B41]; [@B65], [@B66]). Interestingly, loss of function seems more extensive in early onset AD than in later-onset AD, which may be due to compensating systems ([@B9]; [@B139]). More specifically, marked reduction of the 5-HTR~1A~, which is expressed in brain areas known for their role in memory and learning, has been noted in the hippocampus and the frontal cortex during AD progression ([@B211]). This may, however, reflect a compensatory mechanism for reduction of cholinergic receptors in the AD brain, since inhibition of the 5-HTR~1A~ has been implicated in the release of ACh ([@B246]; [@B189]; [@B322]). Another receptor that is affected during AD progression is 5-HTR~2A~, with reductions being noted in the frontal, temporal, parietal and enthorinal cortex and the hippocampus ([@B82]; [@B301]; [@B97]). In a review by [@B322] it was suggested that a decrease in 5-HTR~2A~ may effect cognitive functions in AD patients. A positive correlation between cognitive decline and 5-HTR~2A~ related decrease in the frontal cortex has indeed been noted ([@B210]). Moreover, it was implied that decrease in 5-HTR~2A~ density may be due to pathological accumulation of Aβ ([@B70]; [@B158]). Stimulation of the 5-HTR~4~ may lead to an increase of the non-amyloidogenic pathway *in vitro* ([@B75]; [@B321]), indication for an important role in APP metabolism. Other 5-HTRs with marked reduction in AD are 5-HTR~1B~, 5-HTR~1D~, and 5-HTR~6~ ([@B123]; [@B222]). Additionally, reduction of the former two correlates well with the cognitive decline in AD ([@B123]). Significant decrease (up to 25%) in binding sites of the 5-HTT during AD progression is also to be noted ([@B41]; [@B277]). As part of the monoamine transporter family, the SERT is responsible for removal of serotonin from the synaptic cleft. There seems, however, no correlation between the reduced density of this transporter and BPSD symptoms, as seen in AD ([@B376]).

Most drugs targeting the serotonergic system are used as adjuvant therapy, combatting BPSD symptoms by inhibition of SERT and/or the norepinephrine transporter. Recent meta-analyses have proven their efficacy in treating these behavioral symptoms in AD ([@B11]; [@B150]). Some serotonin reuptake inhibitors have, however, also been evaluated for their possible cognitive enhancement in AD patients (See **Table [2](#T2){ref-type="table"}**). Likewise, increasing interest has been noted for 5-HTR drugs that are able to improve cognition and/or memory in AD. 5-HT~1~-, 5-HT~4~-, and 5-HT~6~ receptors are hereby of particular interest, due to their important role in learning and memory processes ([@B125]), effects which are most likely due to their modulation on glutamatergic and cholinergic transmission, or, in the case of 5-HT-4, due to an enhanced release of ACh upon stimulation of this receptor ([@B322]). An overview of trials that have looked into the clinical benefit of serotonergic drugs on cognitive impairment in AD patients is given in **Table [2](#T2){ref-type="table"}**.

###### 

Enhancement of cognitive functions in AD by drugs that modulate serotonergic neurotransmission ([@B125]; [@B309]).

  Drug                      Mechanism              Trial (Phase)   Outcome                                          Reference/ongoing trail
  ------------------------- ---------------------- --------------- ------------------------------------------------ -------------------------
  Lecozotan (SRR-333)       5-HTR~1A~ antagonist   2               Unsuccessful due to adverse effects              [@B332]
  Xailiproden (SRR57746A)   5-HTR~1A~ antagonist   3               Unsuccessful to demonstrate efficacy             [@B332]
  PRX-03140                 5-HTR~4~ agonist       2               Improvement on ADAS-cog scale                    [@B332]
  SB-742457                 5-HTR~6~ antagonist    2               Improvement on CIBIC+ score and ADAS-cog scale   [@B229]
  Lu-AE-58054 (SGS-518)     5-HTR~6~ antagonist    2               Improvement on ADAS-cog scale and ADL            [@B322]
                                                   3               Ongoing                                          NCT02079246
                                                   3               Ongoing                                          NCT02006654
                                                   3               Ongoing                                          NCT02006641
                                                   3               Ongoing                                          NCT01955161
  PF-05212377 (SAM-760)     5-HTR~6~ antagonist    2               Ongoing                                          [@B322]/NCT01712074
  SUVN-502                  5-HTR~6~ antagonist    2               Ongoing                                          [@B125]/NCT02580305
  Citolapram                SSRI                   4 weeks         Improvement on ADL                               [@B267]
  Fluoxetine                SSRI                   8 weeks         Improvement on MMSE                              [@B251]
  Sertraline                SSRI                   12 weeks        Improvement on ADL                               [@B227]

ADAS-cog, Alzheimer's Disease Assessment Scale-cognitive subscale; CIBIC+, Clinician's Interview-Based Impression of Change; ADL, Activity of Daily Living; MMSE, Mini-Mental State Examination; SSRI, Selective Serotonin Reuptake Inhibitor.

Although much progress has been made in the development of PET- and SPECT radioligands for visualization of the serotonergic system ([@B291]), only a few radiolabeled compounds have been evaluated on AD patients thus far. In the group of the 5-HT~1A~R, only one PET radioligand, 4-\[^18^F\]fluoro-*N*-{2-\[4-(2-methoxyphenyl)-1-piperazinyl\]ethyl}-*N*-(2-pyridinyl)benzamide (\[^18^F\]MPPF, **Figure [8](#F8){ref-type="fig"}**), a reversible, competitive 5-HT~1A~R antagonist, was investigated in patients with MCI and AD ([@B195]; [@B375]). Decrease of \[^18^F\]MPPF binding was noticed in the hippocampus and raphe nuclei of AD patients (as compared to HCs). Furthermore, loss of receptor density in the hippocampus was strongly correlated to a decline in the MMSE score. In patients with MCI, only a small loss of 5-HT~1A~R density was noticed, correlated to only small cognitive decline ([@B195]). \[^18^F\]MPPF is one of many fluoro-analogs of \[^11^C\]WAY100635, the latter one being excessively studied in humans. Yet, no studies on AD patients were performed with \[^11^C\]WAY100635, mainly due its rapid metabolism, making kinetic modeling difficult ([@B291]). \[^18^F\]MPPF does not suffer from these limitations, but is on the other hand a substrate of the P-gp, which could limit its further use in clinic ([@B208]). Imaging of the 5-HT~2~R in AD patients was done by one SPECT- and three PET radiolabeled 5-HT~2~R antagonists, namely 4-amino-*N*-{1-\[3-(4-fluorophenyl)propyl\]-4-methylpiperidin-4-yl}-5-\[^123^I\]iodo-2-methoxybenzamide (\[^123^I\]-R91150), 6-(2-{4-\[4-\[^18^F\]fluorobenzoyl\]piperidin-1-yl}ethyl)-7-methyl-2H,3H,5H-\[1,3\]thiazolo\[3,2-a\]pyrimidin-5-one (\[^18^F\]setoperone), 3-(2-{4-\[4-\[^18^F\]fluorobenzoyl\]piperidin-1-yl}ethyl)-2-sulfanylidene-1,2,3,4-tetrahydroquinazolin-4-one (\[^18^F\]altanserin) and 3-(2-{4-\[4-\[^18^F\]fluorobenzoyl\]piperidin-1-yl}(2,2-^2^H2)ethyl)-2-sulfanylidene-1,2,3,4-tetrahydroquinazolin-4-one (\[^18^F\]deuteroaltanserin) (**Figure [8](#F8){ref-type="fig"}**). In agreement with previous postmortem studies, an overall significant reduction in the cerebral cortex was noted in mild to severe AD patients, compared to their age-matched controls ([@B34]; [@B385]; [@B336]; [@B232]). In the 5-HT~4~R class though, one PET ligand was evaluated on AD patients: \[1-\[^11^C\]methylpiperidin-4-yl\]methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxine-5-carboxylate (\[^11^C\]SB207145), a 5-HT~4~R antagonist (**Figure [8](#F8){ref-type="fig"}**). This radioligand did not display significant differences between mild AD cases and their HCs, although a positive correlation was found with the Aβ density (as measured by \[^11^C\]PiB). Moreover, a negative correlation was noticed between \[^11^C\]SB207145's binding potential and the MMSE score. Authors suggested that upregulation of 5-HT~4~R may take place at a preclinical stage of AD (this in contrast to the other 5-HTRs) and that this may continue through the later AD stages ([@B228]). Finally, (3-amino-4-(2-dimethylamino-methyl-phenylsulfanyl)-benzonitrile) (\[^11^C\]DASB, **Figure [8](#F8){ref-type="fig"}**), a SERT tracer, displayed a more outspoken decrease (25%) of binding in the subcortical serotonergic projection region in depressed, as compared to non-depressed AD patients (mean MMSE score of 18) ([@B277]). Yet, in another clinical study on patients with mild AD (not corrected for depression) no such reduction was found ([@B232]). Authors of the latter study suggest that this discrepancy may, however, lay in both differences in dementia severity as well as methodological differences between these studies ([@B232]). For a more detailed discussion about the current state of other 5-HT PET- and SPECT radioligands, readers are referred to some excellent reviews ([@B337]; [@B291]; [@B29]; [@B208]). These compounds can be used for evaluation of inclusion- and outcome criteria, but also in dose-occupancy studies.

![**Structure of serotonergic PET/SPECT tracers**.](fphar-07-00088-g008){#F8}

Dopaminergic System
===================

The activity of DA, a catecholamine, is mediated through five dopaminergic, metabotropic, G-protein coupled receptors. They are divided into two classes: D~1~-like receptors (D~1~R and D~5~R) and D~2~-like receptors (D~2-4~R), depending on the downstream signaling cascade. Levels of DA are regulated through the activity of the presynaptic DAT, which removes DA from the synaptic cleft to terminate its activity ([@B248]). Dopaminergic neurons are largely located in the midbrain, with many projections throughout the brain ([@B235]), where they are involved in various neurological processes. Of particular importance here is their role in motivation, cognition, and learning ([@B413]). Indeed, around 35--40% of AD patients exhibit extrapyramidal symptoms and more than 70% display extensive apathy ([@B221]; [@B248]). These symptoms might be explained by the significantly reduced levels of DA and its precursor [L]{.smallcaps}-3,4-dihydroxyphenylalanine ([L]{.smallcaps}-DOPA) ([@B356]). Although large involvement of DA in AD is still under debate ([@B299]; [@B373]), several noticeable changes have been documented in the DA receptor density. More specifically, a significant reduced expression of D~1~- and D~2~-like receptors has been documented in the prefrontal cortex and the hippocampus of AD patients ([@B191]; [@B209]). Furthermore, alterations of the D~2~R in AD seems positively correlated to BPSD and verbal memory performance ([@B191]; [@B361]). Conflicting results are, however, reported for the D~2~R density in AD patients (see further) ([@B295]; [@B294]). Contradictory results are also reported for changes in the DAT levels in AD patients ([@B253]; [@B62]). Despite some discrepancy, it is clear that there are important DA changes in the AD brains. Finally, it is to be noted that several *in vivo* experiments on mice, expressing AD like pathology, show that significant behavioral and cognitive deficits can be restored by administering DA reuptake inhibitors and L-DOPA ([@B4]; [@B136]). Aβ oligomers may indeed have an early impact on catecholaminergic transmission ([@B252]).

There are several modes of interventions toward the failing dopaminergic system in AD patients, mostly used to address apathy (the most common BPSD symptom) and extrapyramidal symptoms. One of many approaches is the use of MAO-B inhibitors, which are discussed in Section "Monoamine Oxidase B" of this review. Another therapeutic method is modulation of the DAT transporter, and thus increasing synaptic DA levels. This was done by methylphenidate and dextroamphetamine in several clinical AD studies ([@B122]; [@B152]; [@B212]). Although not selective for the dopaminergic system, an overall improvement was noted in symptoms of apathy on the Apathy Evaluation Scale (AES). There are, however, some concerns about the tolerability of methylphenidate ([@B280]). Other drugs that are frequently used to treat BPSD symptoms in clinical trials (and routine practice) involving AD patients are the antipsychotic drugs quetiapine, aripiprazole, olanzapine, and risperidone. As FDA- and EMA-approved drugs, these drugs act as partial DA receptor agonist or partial DA receptor antagonist (among often interaction with many other targets). Overall improvement on BPSD symptoms was recorded in a large meta-analysis of the use of antipsychotics in AD patients ([@B13]). Nevertheless, caution was advised by the FDA with these drugs, as they were associated with an increase in risk of death, and other severe side effects, among elder people with dementia ([@B13]; [@B90]). Yet another drug, rotigotine, a D~2~R- and D~3~R agonist, was able to show cognitive enhancement on probable AD patients, compared to their age-matched HCs by measuring the cortical excitability and central cholinergic transmission ([@B234]).

Imaging of the dopaminergic system can be done by a number of PET- and SPECT radioligands. Conflicting results are, however, reported between several clinical studies on AD patients, using different PET- and/or SPECT tracers. In a combined PET study, reduced striatal expression of D~1~R, but not D~2~R was seen with D~2~R antagonist 3,5-dichloro-*N*-{\[(2S)-1-ethylpyrrolidin-2-yl\]methyl}-2-hydroxy-6-\[^11^C\]methoxybenzamide(\[^11^C\]raclopride) and D~1~R antagonist (5R)-8-chloro-5-(2,3-dihydro-1-benzofuran-7-yl)-3-\[^11^C\]methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol (\[^11^C\]NNC 756) in AD patients (**Figure [9](#F9){ref-type="fig"}**), compared to age-matched HCs ([@B192]). Striatal uptake of 2-amino-3-\[2-\[^18^F\]fluoro-4,5-dihydroxyphenyl\]propanoic acid (\[^18^F\]FDOPA), a fluorinated form of L-DOPA (**Figure [9](#F9){ref-type="fig"}**), was also unchanged in AD patients, compared to HCs ([@B378]). Conversely, decreased striatal expression of D~2~R with \[^11^C\]raclopride was demonstrated in AD patients (with BPSD symptoms) as compared to their HCs ([@B361]). Similar studies, using *N*-{\[(2S)-1-ethylpyrrolidin-2-yl\]methyl}-2-hydroxy-3-\[^123^I\]iodo-6-methoxybenzamide (\[^123^I\]IBZM) (**Figure [9](#F9){ref-type="fig"}**), a D~2~R antagonist, or methyl (2S,3S)-3-(4-fluorophenyl)-8-\[^11^C\]methyl-8-azabicyclo\[3.2.1\]octane-2-carboxylate (\[^11^C\]β-CFT) (**Figure [9](#F9){ref-type="fig"}**), a cocaine derivative which binds to DAT, showed, respectively, a reduced expression of D~2~R and a reduced DA reuptake ([@B297]; [@B317]). Reduction of DA reuptake sites, as measured by \[^11^C\]β-CFT, was hereby positively correlated to the severity of the extrapyramidal symptoms of AD patients, whereas in the study with \[^123^I\]IBZM, patients did not exhibit any extrapyramidal symptoms. Likewise, a decrease in \[^18^F\]FDOPA striatal uptake was noticed in another study on AD patients, a decrease which was correlated to the cognitive scores of the AD patients ([@B171]). On the other hand, even more confusing, is the fact that in yet another clinical study involving AD patients an increase in D~2~R expression in the striatum was now measured with \[^11^C\]raclopride ([@B313]). Discrepancies between these different studies might, however, be explained by different study populations, and the degree of dementia, since time-dependent dopaminergic receptor changes were also seen in patients with PD ([@B47]). Another role for dopaminergic neuroimaging was displayed by methyl (2S,3S)-8-(3-fluoropropyl)-3-\[4-\[^123^I\]iodophenyl\]-8-azabicyclo\[3.2.1\]octane-2-carboxylate (\[^123^I\]FP-CIT) (**Figure [9](#F9){ref-type="fig"}**), an analog of \[^11^C\]β-CFT. \[^123^I\]FP-CIT was able to differentiate, with high accuracy, patients with AD, and patients with DLB ([@B73]; [@B353]). Overall reduced striatal uptake was noticed in both diseases, but lower binding potentials of \[^123^I\]FP-CIT were reported in DLB than in the case of the AD patients. These scans can greatly improve differential diagnosis between the different neurodegenerative diseases, which often display similar clinical presentations. \[^123^I\]FP-CIT SPECT scans are already used in clinical routine to distinguish DLB- from AD patients ([@B353]). Finally, 5-\[3-\[^18^F\]fluoropropyl\]-2,3-dimethoxy-*N*-{\[1-(prop-2-en-1-yl)pyrrolidin-2-yl\]methyl}benzamide (\[^18^F\]fallypride) (**Figure [9](#F9){ref-type="fig"}**), a D~2~R/D~3~R antagonist, could be used to assess the ideal therapeutic window for the use of antipsychotic drugs ([@B72]), since, as mentioned before, elder people are very sensitive to these drugs. \[^18^F\]fallypride PET scans could consequently assist in antipsychotic dose-occupancy studies, and thus help to provide an ideal antipsychotic strategy in AD patients with extensive BPSD symptoms.

![**Structure of dopaminergic PET/SPECT tracers**.](fphar-07-00088-g009){#F9}

Neuroinflammation
=================

Translocator Protein
--------------------

Formerly known as PBR, the 18 kDa TSPO, is located on the outer membrane of the mitochondria, predominantly in glial cells. As part of a multimeric complex, which is comprised of a VDAC and an adenine nucleotide carrier ([@B239]; [@B59]; [@B78]), several functions are associated with TSPO ([@B244]). They play an essential role in neurosteriod synthesis, by facilitating the transport of cholesterol from the outer to the inner membrane of the mitochondria ([@B286],[@B287]), and hence potentiate the GABAergic neurotransmission through allosteric modulation of the GABA~A~ receptor by neurosteroids ([@B25]; [@B163]; [@B330]). Furthermore, TSPO may have a crucial function in a variety of cellular processes, such as cell proliferation ([@B245]; [@B145]), mitochondrial respiration ([@B155]) and cell apoptosis ([@B206]). In light of TSPO's association with the pathophysiology of neurodegenerative diseases, it has been well established that part of the neurotoxicity caused by tau and Aβ deposits in AD is induction of a neuroinflammatory response ([@B240]; [@B161]), which triggers the upregulation of TSPO in activated microglia and astrocytes. Moreover, this upregulation clearly correlates with the degree of neuroinflammation, making TSPO a valuable target for drug monitoring ([@B384]). Interestingly, in a review by [@B71], it was suggested that TSPO ligands may provide effective tools for treatment of AD through activation of neuroprotective pathways of increased expression of astrocytes and microglial cells, since these mechanisms may have a protective phagocytic role in early AD ([@B250]). Once a more progressed AD state has been reached, neuroinflammation turns chronic and becomes harmful ([@B154]). This view is in contrast with numerous clinical trials, using anti-inflammatory drugs that failed to produce significant improvement in AD patients ([@B357]; [@B383]), although this failure may be attributed to a 'wrong' stage of the disease when therapy was initiated ([@B249]). There are currently no drugs in clinical trials that interact with the TSPO receptor in AD. Drugs that are already described are mainly used for their use against BPSD symptoms ([@B331]; [@B278]). TSPO is, however, an important marker for neuroinflammation, which makes it an interesting target for neuroimaging. PET tracers in this class will thus mainly be used to assess inclusion- and outcome criteria in clinical trials with anti-neuroinflammatory drugs in AD.

The most studied TSPO tracer in patients with CNS disorder is without a doubt *N*-\[(2R)-butan-2-yl\]-1-(2-chlorophenyl)-*N*-\[^11^C\]methylisoquinoline-3-carboxamide (\[^11^C\]PK11195) (**Figure [10](#F10){ref-type="fig"}**), despite its low specific binding and minimal brain uptake ([@B85]). Nonetheless, conflicting results are reported with \[^11^C\]PK11195, but also with several other clinical TPSO tracers, such as *N*-{\[2-\[^11^C\]methoxyphenyl\]methyl}-*N*-(4-phenoxypyridin-3-yl)acetamide (\[^11^C\]PBR28), *N*-(5-fluoro-2-phenoxyphenyl)-*N*-{\[2-\[^11^C\]methoxy-5-methoxyphenyl\]methyl}acetamide (\[^11^C\]DAA1106), (2-\[^11^C\])ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo\[9.6.2.0^2,7^0^8,18^.0^15,19^\]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate (\[^11^C\]vinpocetine), *N*-({2-\[2-\[^18^F\]fluor-ethoxy\]-5-methoxyphenyl}methyl)-*N*-\[2-(4-methoxyphenoxy)pyridin-3-yl\]acetamide (\[^18^F\]FEMPA), *N*-({2-\[2-\[^18^F\]fluoroethoxy\]-5-methoxyphenyl}methyl)-*N*-(2-phenoxyphenyl)acetamide (\[^18^F\]FEDAA1106) and *N,N*-diethyl-2-(2-{4-\[2-\[^18^F\]fluoroethoxy\]phenyl}-5,7-dimethylpyrazolo\[1,5-a\]pyrimidin-3-yl)acetamide (\[^18^F\]DPA-714) (**Figure [10](#F10){ref-type="fig"}**). While a majority of clinical trials was able to show significant tracer uptake in at least one brain area in AD patients, several other studies failed to differentiate MCI or even HCs from AD ([@B382]; [@B355]). Apart from low signal-to-noise ratios and low brain uptake of some of these compounds, there are many possible explanations for the discrepancies in TSPO expression, as measured by PET in these clinical trials involving AD patients ([@B178]). It is, however, important to realize, as suggested before ([@B178]), that many patients exhibit different TSPO expression levels, depending on the specific polymorphism in the TSPO gene, resulting in intersubject variability in the binding affinities of TSPO PET tracers ([@B279]). Increasing efforts have therefore been focused toward compounds that are insensitive toward TSPO polymorphism, but also toward compounds for other neuroinflammatory targets (such as MAO-B, see Section Monoamine Oxidase B). Furthermore, overexpression of TSPO in both astrocytes and microglial cells make it difficult to differentiate MCI from AD patients ([@B107]; [@B178]). Nevertheless, \[^18^F\]DPA-714 is currently being used to assess the degree of neuroinflammation in AD patients in two clinical trials (CTI: NCT02377206 and NCT02062099). For a more detailed discussion of the current status of PET development for TSPO, or neuroinflammation in general, readers are referred to several other reviews ([@B276]; [@B382]; [@B178]).

![**Structure of TSPO PET tracers**.](fphar-07-00088-g010){#F10}

Monoamine Oxidase B
-------------------

Monoamine oxidases are mitochondrial bound enzymes, as a member of the flavin-containing amine oxidoreductases protein family, in the CNS primarily found in astrocytes. They are responsible for oxidative deamination of monamines of both endogenous and exogenous sources, regulating the physiological activity of neurotransmitters as serotonin, DA, and noradrenaline ([@B358]). There are two types of isoforms, MAO-A and MAO-B, which differ in inhibitor sensitivity and substrate selectivity, although there is an overlap to some degree ([@B40]). Increased MAO-B activity has been noted in AD in both brain and blood platelets ([@B1]; [@B3]; [@B352]), the severe upregulation in the brain mainly being a consequence of a plaque associated neuroinflammatory response by reactive astrocytes ([@B181]; [@B338]). Furthermore, during their catalytic deamination, MAOs produce neurotoxic byproducts such as hydrogen peroxide, which are one of the main culprits in oxidative stress, contributing to the formation of amyloid plaques ([@B165]; [@B420]). Since MAOs play a key role in the regulation of several important neurotransmitters, cognitive impairment, due to pathological upregulation of MAOs has also been demonstrated ([@B95]). MAO inhibitors may therefore have a significant neuroprotective role in AD. Since MAO-B is the main isoform present in brain ([@B315]; [@B350]) and inhibition of MAO-B proved to be useful as therapeutic approach in PD, focus has mainly been targeted toward MAO-B inhibition in AD ([@B369]). So far, five different drugs have inhibited MAOs in clinical trials involving AD patients ([@B57]). Two of them, selegiline ([L]{.smallcaps}-deprenyl) and rasagiline (Azilect), irreversible MAO-B selective inhibitors, are established drugs in the treatment of PD, delaying the need for DA replacement therapy ([@B32]; [@B215]; [@B398]). While selegiline initially showed promise in clinical trials involving AD patients, demonstrating modest improvements on cognitive and behavioral functions ([@B113]), a comprehensive meta-analysis showed no justification for the use of selegiline in the treatment of AD, since there was a lack of overall significant benefit ([@B33]). The beneficial effect of rasagiline is yet to be evaluated in AD patients. A Phase II proof of concept trial in patients with mild to moderate AD is, however, underway (CTI: NCT02359552). Interestingly, rasagiline formed the basis of two other multi-target drugs, ladogistil (TV3326), and M-30. The former drug is a MAO-B inhibitor and AChE inhibitor, the latter a MAO-A and MAO-B inhibitor ([@B417]). Both compounds are thought to modulate APP expression levels (by stimulating the non-amyloidogenic pathway) and both may have neuroprotective and neurorestorative functions ([@B314]; [@B417]). Phase II trials with ladogistil on mild to moderate AD patients have been completed, but results are yet to be published (CTI: NCT01354691). These drugs may hold promise as multi-target approach for treatment of AD, being able to tackle various pathophysiological changes at once ([@B417]). Finally, EVT 301 (RO4477478), a reversible MAO-B inhibitor was evaluated on four AD patients (MMSE score: not specified) in a dose-finding study, using \[^11^C\]deprenyl-D2 (\[^11^C\]DED) PET (See further, **Figure [11](#F11){ref-type="fig"}**) to assess MAO-B occupancy levels. Seven days of treatment resulted hereby in an almost complete dose-occupancy of MAO-B ([@B156]). No further clinical trials, to our knowledge, have since been performed with this drug.

![**Structure of MAO-B PET tracer**.](fphar-07-00088-g011){#F11}

Only one MAO binding PET tracer has been elevated on AD patients thus far: \[^11^C\]methyl\[(2R)-1-phenylpropan-2-yl\]\[(1,1-^2^H2)prop-2-yn-1-yl\]amine (\[^11^C\]DED), an irreversible MAO-B inhibitor ([@B156]; [@B58]; [@B69]). Increased uptake of \[^11^C\]DED was observed in patients with MCI (who responded positively to a \[^11^C\]PIB scan), suggesting that astrocytocis may be an early event in the development of AD. Clinical AD studies with other emerging (fluorine-18 labeled) MAO radiotracers are yet to be published ([@B276]; [@B116]).

Conclusion
==========

This review demonstrates that there are multiple approaches to be considered when developing disease altering drugs for AD. Important to notice is that each of these pathways is linked to the pathophysiological processes of (often many) other targets, hence a multi-target approach, addressing various pathophysiological changes at once, will be the way forward. Concordant neuroimaging techniques, such as PET and SPECT, could hereby greatly improve therapeutic monitoring, but also significantly aid with the proposal of current inclusion- and outcome criteria in large clinical studies. Moreover, once a disease altering drug has been found, PET/SPECT could eventually be used as standard test to assess and follow up disease progression ([@B22]). Still, there are a few important factors to take in consideration. One of them is the need for quantitative PET assessment, especially during evaluation of novel therapies, to allow quantitative and accurate evaluations. Visual inspection or simplified models (such as SUV) are indeed less robust, as they are influenced by several physiological and technical factors ([@B36]; [@B371]). The other side of the coin is, however, that quantitative PET assessment is very time-consuming, which limits capacity and throughput which are essential in large multi-center trials. Another crucial issue is the loss of BBB function during AD progression, which could greatly affect drug dosage and bioavailability of novel AD therapeutics. One way of monitoring the viability of the BBB is by looking at the P-gp function. Several promising PET candidates are now under development for this purpose ([@B360]), and a pilot study to assess the P-gp function in AD patients is currently ongoing (ECT: 2013-001724-19). Finally, there is a great need for a thorough preclinical evaluation of the mechanism of action. This could not be better demonstrated than by the rise and fall of dimebon. Initially developed as an antihistaminic drug in the former USSR, dimebon demonstrated significant improvement on the ADAS-cog-, MMSE-, and CIBIC+ scales in a 6-month Phase II trial on AD patients in Russia ([@B28]). Consequently, a multi-national Phase III trial was launched, but this trial failed to show any significant improvement on mild to moderate AD patients, as compared to placebo ([@B28]). In a synopsis by Bezprozvanny ([@B28]), failure was largely attributed to poor understanding of the proper mechanism of action in preclinical studies and the lack of objective biomarkers to assess the true therapeutic response in clinical trials. In the last decade, most clinical trials aiming to find AD combatting drugs ultimately failed to produce (convincing) positive results. Although there may be many explanations for this overall failure, thorough preclinical assessment remains an important factor.
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5-HT

:   5-hydroxytryptamine

5-HTRs

:   5-HT receptors

5-HTT

:   5-HT transporter

α-APP

:   α-amyloid precursor protein

Aβ

:   amyloid beta

ACh

:   acetylcholine

AChE

:   acetylcholinesterase

AD

:   Alzheimer's disease

ADAS-cog

:   Alzheimer's disease assessment scale-cognitive subscale

ALA

:   α-lipoic acid

APP

:   amyloid precursor protein

BACE1

:   β-site APP-cleaving enzyme 1

BBB

:   blood--brain barrier

BPSD

:   behavioral and psychological symptoms of dementia

BZDs

:   benzodiazepines

CBD

:   corticobasal degeneration

ChAT

:   choline acetyltransferase

CIBIC+

:   clinician's interview-based impression of change

CNS

:   central nervous system

CSF

:   cerebrospinal fluid

CT

:   computerized tomography

CTI

:   clinical trial identifier

D~1~R

:   dopamine~1~-like receptors

DA

:   dopamine

DAT

:   dopamine transporter

DLB

:   dementia with Lewy bodies

ECT

:   EudraCT-number

EMA

:   European medicines agency

FDA

:   food and drug administration

FTD

:   frontal temporal dementia

GABA

:   gamma-amino butyric acid

GSK

:   glycogen synthase kinase

HCs

:   healthy controls

mAChR

:   muscarinic acetylcholine receptor

MAPT

:   microtubule-associated protein tau gene

MCI

:   mild cognitive impairment

MMSE

:   mini-mental state examination

MOAs

:   monoamine oxidases

MRI

:   magnetic resonance imaging

nAChRs

:   nicotinic acetylcholine receptors

NFTs

:   neurofibrillary tangles

PBR

:   peripheral benzodiazepine receptor

PET

:   positron emission tomography

P-gp

:   permeability glycoprotein

PHFs

:   paired helical filaments

PSP

:   progressive supranuclear palsy

p-tau

:   phosphorylated tau

rCBF

:   regional cerebral blood flow

SERT

:   5-HT reuptake transporter

SP

:   senile plaques

SPE(C)T

:   single photon emission (computed) tomography

TSPO

:   translocator protein

VDAC

:   voltage dependent anion channel.
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